Altamira Therapeutics Ltd.
CYTOF- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001601936
No open-market purchases or sales by Altamira Therapeutics Ltd. insiders were filed in the last 90 days; 1 institution reported holding it in 13F filings for Q2 2026, worth $0 in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Altamira Therapeutics Ltd. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 6 | 9 | +3 |
| Shares | 73.8K | 889.3K | +815.5K (+1,105.5%) |
| Value | $47.3K | $217.2K | +$170.0K (+359.5%) |
New holders (3)
Institutions that held Altamira Therapeutics Ltd. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Armistice Capital, LLC | 829,000 | $202.7K | 0.01% |
| Susquehanna International Group, LLP | 10,185 | $2.46K | 0.00% |
| XTX Topco Ltd | 10,131 | $2.44K | 0.00% |
Sold out (0)
Institutions that held Altamira Therapeutics Ltd. at the end of Q2 2023 and filed for Q3 2023 without it.
None.